Legend Biotech

Lung cancer remains one of the most challenging diseases to treat, and the need for innovation has never been greater. At Legend, we are committed to advancing the science of #CellTherapy to help change what’s possible for patients with difficult-to-treat solid tumors, including #LungCancer. By harnessing the power of the immune system, we aim to bring hope where few options exist. This #WorldLungCancerDay, we stand with patients, caregivers, and the global lung cancer community to amplify #LungCancerAwareness and remain committed to driving bold science forward.

In celebration of #NationalInternDay, we proudly recognize the talented university students who joined us for a summer internship at Legend Biotech's Corporate Headquarters in Somerset, NJ.🌟   Our interns have explored the various facets of our business, engaging in weekly Lunch & Learn sessions with teams across the company and gaining valuable, real-world insights into the biotech industry.   #FutureLeaders #CellTherapy #FutureOfBiotech #BiotechCareers #InternshipExperience

Today begins a new campaign to educate #MultipleMyeloma patients about our #CART #CellTherapy, a single infusion that’s helped thousands make #time4more. https://lnkd.in/eEX3ebBG

#LegendNews: Legend Biotech will host a webcast to share 2025 second-quarter financial results on August 11 at 8 a.m. ET. Register to join here: https://lnkd.in/eR9xrznc $LEGN #CART #CellTherapy

Our #LEGENDary global team came together to celebrate our shared commitment to quality and strengthen the bonds that drive our mission forward. ☀️🌮🎉   At our Somerset, NJ headquarters, we enjoyed a fantastic picnic — a perfect day of good food and great company! Meanwhile, our team members in Ghent, Belgium, gathered to celebrate the Solstice and our collective achievements.   A big thank you to everyone who made these events memorable. Moments like these remind us that behind every innovation is a united team working to transform the future of #CellTherapy. #EmployeeEngagement #TeamSpirit #CompanyCulture

The FDA has announced the removal of REMS (Risk Evaluation and Mitigation Strategy) requirements for all approved BCMA‑ and CD19‑targeted CAR‑T therapies—meaning fewer administrative hurdles, broader treatment access, and improved convenience for patients.   This is a pivotal milestone for #CART #CellTherapy. The FDA’s move reflects growing clinical experience and robust safety protocols, and empowers community oncologists and patients alike. We're proud to play a part in expanding access to advanced cell therapies—and this shift dovetails with our commitment to making CAR‑T more practical, scalable and patient-centric.

We were proud to take part in Nerdland Festival 2025 in Belgium, where innovation, collaboration, and curiosity converge.   Our #LEGENDary team connected with students, scientists, and future leaders in biotech through our CAR-T Showcase Experience and inspiring sessions on the Talent Stage. Our interactive installations shared insights into #CellTherapy, our work at Legend Biotech, and what it means to bring transformative science to patients worldwide.   Thank you to the organizers for helping the next generation of innovators explore careers in life sciences and ask bold questions that drive progress.   #NERDLand2025 #STEMEducation #InspiringInnovation #FutureScientists #WeAreLegend

Our CEO Dr. Ying Huang met with OncoDaily at the #ASCO2025 Annual Meeting to discuss the groundbreaking long-term CARTITUDE-1 data generated by our #CART #CellTherapy for #MultipleMyeloma.   Highlights include: ✅ One-third of patients remain progression-free five years after a single infusion. ✅ Median overall survival extended to 60 months. ✅ Deep responses with MRD negativity in many patients.   Watch the full clip: https://lnkd.in/eHTMGyps 

#EHA2025 is underway! The Legend Biotech team is proud to join the global #Oncology community at the European Hematology Association (EHA)’s 2025 Congress to share insights and explore the latest innovations in #Hematology. 📅 Don’t miss our presentation on Thursday, June 12, 2025, 17:00-18:15 CEST for our encore oral presentation discussing our groundbreaking five-year survival data for our #CART #CellTherapy in relapsed/refractory #MultipleMyeloma. We look forward to connecting and collaborating with fellow scientists, clinicians, and innovators driving progress in hematologic care. #EHA25 #HealthcareInnovation #Immunotherapy

Our #LEGENDary team in Belgium recently took part in the Kom op tegen Kanker cycling challenge to raise support for vital #CancerResearch. 🚴♂️ Over four days, they pedaled with purpose to cycle 1,000 km, a remarkable achievement. Congrats to the entire team! #WeAreLegend #CyclingForACause #MakingADifference #KomOpTegenKanker